Japanese pharmaceutical firm Eisai Co. is set to start clinical trials in the United States of its experimental drug eritoran in the battle against coronavirus, with results potentially available by the year-end, the company said Wednesday.
Eisai will test eritoran, initially developed to treat severe sepsis, in conjunction with U.S.-based nonprofit organization Global Coalition Adaptive Research, formed of medical experts tasked with discovering cures for rare and deadly diseases.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.